Rituximab or Cyclophosphamide Combined With Steroids in Idiopathic Membranous Nephropathy
Status:
Not yet recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This wasa prospective, multicenter, randomized, controlled trial. Patients with idiopathic
membranous nephropathy (IMN) were randomly divided into intervention or control group.
Intervention group was given rituximab combined with steroid in induction therapy. After 6
months, patients in the rituximab treatment group who had decreased 24h urinary protein by
>25% but did not achieve CR were given rituximab maintenance therapy. Patients in control
group were treated with cyclophosphamide combined with prednisolone.The response rate at 24
months (including the proportion of participants with complete and partial responses at 24
months after enrollment) was measured.